GLP-1s have reshaped obesity treatment and healthcare in 2023. What's next in 2024? Accolade's report unpacks trends, costs, and HR insights to help guide employers toward understanding their role in the care continuum of treating obesity
In 2023, GLP-1 medications have stormed the healthcare scene as a treatment for obesity. But what does 2024 hold? Our report dives into the shifting attitudes of benefits planners towards these treatments. Discover key insights from HR decision-makers, explore cost implications, and understand the rising demand for trusted information.
Are you prepared to optimize your benefits package for an increasingly health-conscious world? Get ahead with Accolade’s comprehensive employee health trends report.
It can take 26 days or more to see a doctor. In that time, you could sail from Tokyo to New York City, bike to Indianapolis, and still have to wait three days for your appointment. Learn how Accolade can reduce the wait and improve healthcare outcomes...
View nowDiscover how a leading hospitality company transformed employee engagement and health benefits utilization with Accolade Plus...
Read nowAchieve a successful open enrollment with our comprehensive Playbook. Discover strategies to maximize employee engagement, streamline communication, and ensure a seamless benefits enrollment process. Navigate open enrollment with confidence and efficiency...
Read now
